- Home
- PRQR vs OABI Comparison
PRQR vs OABI Comparison
Compare PRQR & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRQR
- OABI
- Stock Information
- Founded
- PRQR 2012
- OABI 2012
- Country
- PRQR Netherlands
- OABI United States
- Employees
- PRQR N/A
- OABI N/A
- Industry
- PRQR Biotechnology: Pharmaceutical Preparations
- OABI Biotechnology: Pharmaceutical Preparations
- Sector
- PRQR Health Care
- OABI Health Care
- Exchange
- PRQR Nasdaq
- OABI Nasdaq
- Market Cap
- PRQR 250.7M
- OABI 239.0M
- IPO Year
- PRQR 2014
- OABI N/A
- Fundamental
- Price
- PRQR $2.24
- OABI $1.39
- Analyst Decision
- PRQR Strong Buy
- OABI Strong Buy
- Analyst Count
- PRQR 7
- OABI 3
- Target Price
- PRQR $8.14
- OABI $6.67
- AVG Volume (30 Days)
- PRQR 600.3K
- OABI 544.1K
- Earning Date
- PRQR 11-06-2025
- OABI 11-04-2025
- Dividend Yield
- PRQR N/A
- OABI N/A
- EPS Growth
- PRQR N/A
- OABI N/A
- EPS
- PRQR N/A
- OABI N/A
- Revenue
- PRQR $18,859,556.00
- OABI $21,094,000.00
- Revenue This Year
- PRQR N/A
- OABI N/A
- Revenue Next Year
- PRQR N/A
- OABI $48.89
- P/E Ratio
- PRQR N/A
- OABI N/A
- Revenue Growth
- PRQR N/A
- OABI 3.36
- 52 Week Low
- PRQR $1.07
- OABI $1.22
- 52 Week High
- PRQR $4.21
- OABI $4.87
- Technical
- Relative Strength Index (RSI)
- PRQR 38.89
- OABI 34.62
- Support Level
- PRQR $2.61
- OABI $1.32
- Resistance Level
- PRQR $2.81
- OABI $1.56
- Average True Range (ATR)
- PRQR 0.22
- OABI 0.09
- MACD
- PRQR -0.08
- OABI -0.02
- Stochastic Oscillator
- PRQR 2.27
- OABI 16.09
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.